AtriCure, Inc. - ATRC STOCK NEWS

AtriCure, Inc. (Nasdaq: ATRC) announced FDA approval for the EPi-Sense® System, which treats long-standing persistent atrial fibrillation (Afib). The CONVERGE™ trial demonstrated a 29% absolute efficacy improvement at 12 months and a 35% improvement at 18 months for patients using hybrid AF therapy compared to traditional methods. The therapy reduces ablation times by over 40 minutes, enhancing lab efficiency. With over three million patients affected in the U.S., this treatment aims to change care standards for difficult Afib cases, promising improved outcomes and long-term freedom from arrhythmias.

AtriCure, Inc. (Nasdaq: ATRC) reported first quarter 2021 revenue of $59.3 million, an increase of 11.4% year-over-year. U.S. revenue grew 15.7% to $50.3 million, driven by increasing sales in key product categories, while international revenue declined 8.1% to $9 million due to COVID-19 restrictions. The gross profit rose to $44.5 million with a gross margin of 75.1%. The company reported a net loss of $15.9 million, or $0.38 per share, an improvement from $0.42 per share a year earlier. AtriCure projects full year 2021 revenue between $252 million and $256 million.

AtriCure, Inc. (Nasdaq: ATRC) has appointed B. Kristine Johnson as Board Chair. Scott Drake and Mark Lanning will not seek re-election in May 2021. Johnson, who has been on the board since 2017, is President of Affinity Capital Management and has extensive experience in the healthcare sector, including a 17-year career at Medtronic. Drake, who has served on AtriCure's Board since 2013, and Lanning, a board member since 2006, have both contributed significantly to the company's growth.

AtriCure, a leader in Afib treatments, will release its Q1 2021 financial results on April 27, 2021. The company will also host a conference call at 4:30 PM ET to discuss these results, accessible by calling (844) 884-9951 (domestic) or (661) 378-9661 (international), using conference ID 3349395. AtriCure is recognized for innovative solutions, including the FDA-approved Isolator Synergy Ablation System for persistent Afib and the widely used AtriClip Left Atrial Appendage Exclusion System.

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in the Oppenheimer 31st Annual Healthcare Conference. The presentation is scheduled for March 16, 2021, at 1:10 p.m. Eastern Time. AtriCure offers innovative solutions, including the Isolator® Synergy™ Ablation System, the first FDA-approved device for treating persistent Afib, and the AtriClip® Left Atrial Appendage Exclusion System, the most widely sold LAA management device globally. For more details, visit AtriCure's investor page.

AtriCure, Inc. (Nasdaq: ATRC) reported its fourth quarter and full year 2020 financial results, revealing a 5.9% decline in Q4 revenue to $57.7 million, with a full year revenue decrease of 10.5% to $206.5 million, attributed to COVID-19 impacts on surgical procedures. Gross profit in Q4 was $42.4 million with a margin of 73.5%. Adjusted EBITDA improved to a positive $1.7 million in Q4. For 2021, revenue guidance is projected at $250 million, with anticipated adjusted EBITDA losses of $10 million. The first quarter forecast revenue ranges from $55 million to $57 million.

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), has announced its participation in the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 8:00 a.m. ET. The event will feature a live and archived audio webcast available on the company's website. AtriCure’s innovative technologies, including the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System, are widely utilized for Afib treatment, impacting over 33 million individuals globally. For further details, visit AtriCure.com.

AtriCure, Inc. (Nasdaq: ATRC) will release its fourth quarter and full year 2020 financial results on February 23, 2021.

The company will host a conference call at 4:30 p.m. ET on the same day to discuss these results. Interested parties can join the call via phone or listen to a live audio webcast on AtriCure's corporate website. AtriCure specializes in innovative technologies for treating atrial fibrillation (Afib) and left atrial appendage (LAA) management, offering FDA-approved devices that lead the market.

AtriCure, Inc. (ATRC) announced its preliminary financial results for Q4 and full-year 2020, reporting revenue of approximately $57.7 million in Q4, a 6% decline year-over-year, and about $206.5 million for the full year, down 11%. The company acknowledged the impact of COVID-19 on procedure volumes but noted a sequential revenue increase of 5% from Q3 2020. AtriCure emphasized its strong financial position and strategic progress, highlighting upcoming catalysts for growth in 2021, including new procedures and clinical trial data.